Orient Pharma Co. Ltd. (4166.TWO) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · Taiwan
Orient Pharma Co. Ltd. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 1.22 bn TWD | 1.40 bn TWD |
| Gross profit | 651.56 m TWD | 790.72 m TWD |
| Operating income | 173.91 m TWD | 267.06 m TWD |
| EBIT | 177.09 m TWD | 252.55 m TWD |
| Net income | 107.37 m TWD | 208.44 m TWD |
| Diluted EPS – continuing operations | 0.48 TWD | 0.86 TWD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Orient Pharma Co. Ltd.
Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based in Taipei, Taiwan.
More stocks
- Admicom Oyj (ADMCM.HE)
- Topco Technologies (3388.TWO)
- Exsitec Holding AB (EXS.ST)
- Dream Security co. Ltd (203650.KQ)
- Sapien Semiconductors Inc. (452430.KQ)
- Samyoung Elec (005680.KS)
- Vitzro Nextech (488900.KQ)
- F&M BANK CORP (FMBM)
- Traeger, Inc. (COOK)
- Sangoma Technologies Corp (STC.TO)
- Magatouch Co.,Ltd. (446540.KQ)
- Stars Microelectronics (Thailand) PCL (SMT.BK)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.